Information Provided By:
Fly News Breaks for October 1, 2015
PFE, BMY, VRX, TEVA, AGN
Oct 1, 2015 | 07:39 EDT
JPMorgan analyst Chris Schott says the recent pullback in shares of pharma companies creates "compelling" opportunities. The analyst sees no structural changes that will significantly impact the U.S. drug market for the foreseeable future and believes fundamentals across the sector remain intact. He recommends increasing exposure to large-cap names Allergan (AGN), Teva (TEVA), Valeant (VRX), Bristol-Myers (BMY) and Pfizer (PFE).